Last reviewed · How we verify
APX3330
Inhibits the enzyme TGFBR2
Inhibits the enzyme TGFBR2 Used for Treatment of diabetic retinopathy.
At a glance
| Generic name | APX3330 |
|---|---|
| Also known as | E3330 |
| Sponsor | Ocuphire Pharma, Inc. |
| Drug class | TGF-β receptor inhibitor |
| Target | TGFBR2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
APX3330 is a small molecule inhibitor of TGFBR2, which is involved in the TGF-β signaling pathway. This inhibition is thought to reduce fibrosis and inflammation in the eye.
Approved indications
- Treatment of diabetic retinopathy
Common side effects
- Increased intraocular pressure
- Cataract
- Eye pain
Key clinical trials
- Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy (PHASE2)
- A Study of APX3330 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |